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was designed to assess efficacy and safety of teriflunomide, a novel oral disease
modifier, in RMS patients. The utility score, a measure of health-related quality of
life, was calculated via the EQ-5D questionnaire assessed alongside the trial. Using
baseline data, a cross-sectional analysis was performed to identify factors associ-
ated with utility scores using a multivariate regression linear model. This model
includes the following factors; expanded disability status scale (EDSS) score, type of
multiple sclerosis (relapsing remitting (RRMS) versus progressive relapsing (PRMS),
region, number or relapses within the past 2 years, previous MS medication, gen-
der, time (years) since first diagnosis of MS and burden of disease defined by mag-
netic resonance imaging. RESULTS: Three variables demonstrated a significant
negative impact on utility values: the functional disability level as assessed by
EDSS score (when EDSS score increases), PRMS versus RRMS and Eastern European
countries versus North American countries. The major influencing factor, consis-
tent with other analyses, was the EDSS score with the following disutility esti-
mates: EDSS[1-2[-0.021, p0.52; EDSS[2-3[-0.081, p0.0128; EDSS[3-4[-0.176,
p0.0001; EDSS[4-5[-0.237, p0.0001; EDSS[5-6[-0.231, p0.0001; EDSS[6-7[-
0.257, p0.0001]. In addition, disutilities associated with PRMS versus RRMS and
Eastern Europe region versus North American were respectively -0.073 (p0.0028)
and -0.038 (p0.0361). CONCLUSIONS: In RMS patients, these results confirm the
major impact of functional disability on patients’ utility. These analyses also pro-
vided disutility estimates per EDSS score, disutilities for PRMS versus RRMS and for
Eastern Europe versus North American region. The later probably reflecting cul-
tural differences in health status perception.
PND37
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OBJECTIVES: To examine resource utilization associated with the use of Rasagiline
or Selegiline, two commonly prescribed MAOB inhibitors for the treatment of Par-
kinson’s Disease (PD). METHODS: Data for this retrospective study were obtained
from the US i3 LabRx database over the time period from January 1, 2006 through
December 30, 2010. Patients were included in the analysis if they were prescribed
Rasagiline or Selegiline (with first such date identified as the index date), were
diagnosed with PD (ICD-9 code 332.0), and had continuous insurance coverage from
6 months prior through 12 months post index date. Analyses are primarily descrip-
tive in nature, with differences in categorical variables analyzed using chi-square
statistics and differences in continuous variables analyzed using t-statistics.
RESULTS: There were 1242 individuals included in the study - 926 initiated on
Rasagiline and 316 initiated on Selegiline. Patients initiated on Rasagiline, com-
pared to those intitiated on Selegiline, were significantly younger (63.2 years vs.
65.4 years; P0.0020). Patients initiated on Rasagiline were significantly less likely
to be diagnosed with chest pain (16.41% vs. 21.52%; P0.0402) or headaches (4.97%
vs. 9.49%; P0.0037). Patients who intitated on Rasagiline were significantly more
likely to visit a neurologist (93.63% vs. 89.24%; P0.0105). Compared with Selegiline
use, initiation on Rasagiline was associated with significantly fewer inpatient visits
(1.58 vs. 2.94; P0.0236) and significantly shorter hospital length of stay (4.71 days
vs. 8.78 days; P0.0216). CONCLUSIONS: Results from this retrospective study in-
dicate that, patients who initiated therapy with Selegiline, compared to Rasagiline
were more likely to experience side effects of chest pain or headaches. In addition,
these patients were more likely to have a greater resource utilization due to the
number and significantly longer lengths of hospitalizations.
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OBJECTIVES: This study aimed to identify the socioeconomic burden of HD in five
European countries METHODS: The survey was conducted in Germany, Italy,
France, Poland and the USA. The following patient data were collected: clinical
symptoms (motor, behavioral and psychiatric), functional/independence score,
QoL (H-QoLI, SF-36, EQ-5D), resource utilization, GP and specialist visits, other
healthcare professional visits, hospitalization, nursing home, social services, al-
lowance, medical device and daily out of pocket expenses. The following data were
collected from caregivers: time spent and working days lost caring for the patient,
out of pocket expenditure, caregiver quality of life. RESULTS: To date, 175, 124, 44,
60 and 134 patients were included in respectively France, Italy, Germany, Poland
and US. The populations were reasonably homogeneous regarding sociodemo-
graphic characteristics and severity such as age (48-56) and disease duration (6-10
years except for the Poland: 4 years). The average number of monthly visits to GP
was 0.76-1.32, to neurologist 0.49-1.12, to physiotherapist 0.09-5.59. The percentage
of patients admitted to hospital during the last 6 months was between 1% (USA)
and 19% (France). The mean ( SD) health utility (EQ-5D) ranged from 0.25 (0.46) in
France to 0.47 (0.37) in Germany. Caregivers spent between 6 (USA) and 22 hours/
day (Italy, Poland) caring for patients and their monthly expenses amounted to
€295 (Poland) to $2391 (USA). Caregivers also had reduced QoL. CONCLUSIONS: The
initial results indicated significant differences in access to health care and resource
use. France has the largest health care resource consumer by far. Countries that
use little health care resources compensate by a significantly larger caregiver in-
volvement. More data will be presented.
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OBJECTIVES: The impact of hereditary angioedema (HAE) on patients’ health re-
lated quality of life (QoL) extends beyond the acute attack period. This study was to
value the disutility of living with HAE outside of the acute attack period, according
to different emergency treatments available to the patient. METHODS: The study
used a vignette/health state scenario based approach and standard gamble meth-
odology. The health states described three different circumstances faced by pa-
tients with HAE in terms of availability of emergency medications should they
suffer a swelling attack: Scenario A: HAE without any effective emergency medi-
cation; Scenario B: HAE with effective emergency medication available in hospital;
Scenario C: HAE with effective emergency medication available for self-adminis-
tration. The health state descriptions were based evidence from on relevant clini-
cal trials, burden of disease and QoL studies and HAE treatment guidelines, sup-
ported by clinical expert opinion. The standard gamble survey was web based/
administered online. Respondents were recruited from an existing consumer
research panel. RESULTS: A total of 201 respondents completed the survey; 91%
were prepared to gamble with death to achieve perfect health in at least one of the
three health states. The mean utility weighting elicited for health state C was
significantly higher than either weightings elicited for health state B (0.75 [95%CI.
0.71, 0.79] versus 0.64 [95% CI 0.60, 0.69]; p0.001), or for health state A (0.75 [95%CI.
0.71, 0.79] versus 0.62 [95% CI 0.58, 0.67]; p0.001). There was no statistical differ-
ence between the utilities elicited for health states B and A. CONCLUSIONS: The
results demonstrate the recognition of and value placed on the QoL benefits pro-
vided by the availability of and immediate access to a self-administered emergency
medication for HAE over that provided by treatment available only in the hospital
accident and emergency treatment setting.
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OBJECTIVES: Health state utility values are the metric preferred by health care
decision makers to examine the relative value of various treatments to treat mi-
graine, including those that reduce the severity of migraine pain. This cross-sec-
tional, observational study aimed to estimate utility values for different levels of
migraine pain severity.METHODS:One hundred six participants from the UK (UK),
diagnosed with migraine, completed the EQ-5D™ to evaluate their health status for
mild, moderate, and severe levels of migraine pain severity for a recent migraine
attack and for current health (without migraine) defined as health status within 7
days post-attack, with no residual migraine symptoms. T-tests were used to com-
pare mean utility values between each level of severity to evaluate whether there
were significant differences in mean utility scores by migraine severity; Wilcoxon
signed rank test was also performed. RESULTS: Utility scores for each health state
were found to be significantly different from perfect health (p0.0001) and one
another (p0.0001). As severity worsened, utility decreased and the lowest mean
utility, -0.20 (95% confidence interval [CI]: -0.27-0.13), was for severe migraine
pain. Compared to current health (without migraine), utility decrements were 0.21,
0.34, and 1.07 for mild, moderate, and severe migraine pain states respectively. The
smallest difference in mean utility scores was between mild and moderate mi-
graine pain (0.13) and the largest difference in mean utility scores was between
current health (without migraine) and severe migraine pain (1.07). CONCLUSIONS:
Migraine pain severity was associated with significantly lower utility compared
with perfect health, with higher levels of pain severity associated with lower utility.
Severe migraine pain was considered a health state worse than death. Our results
can be used in cost-utility models examining the relative economic value of ther-
apeutic strategies for migraine in the UK.
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OBJECTIVES: H-QoL-I is a quality-of-life indicator specific to the Huntington’s Dis-
ease (HD), with 3 dimensions: motor function, psychology and socializing. It has
been validated in several countries (France, Italy, Poland, Germany and United
States). We compared several methods for mapping H-QoL-I onto EQ-5D and thus
derive utility values from H-QoL-I.METHODS: This analysis was based on a sample
of 315 HD patients who participated in an international survey on the burden of HD,
and completed H-QoL-I and EQ-5D, with help from caregivers if necessary. EQ-5D
index scores were calculated based on UK time trade-off tariff. The sample was
divided into 70% derivation and 30% validation sets. We compared three methods
to estimate patient’s utility as a function of 11 H-QoL-I items: ordinary least-
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